Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden
Titel:
Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden
Auteur:
Srivastava, Tushar Prabhu, Vimalanand S. Li, Haojie Xu, Ruifeng Zarabi, Natalie Zhong, Yichen Pellissier, James M. Perini, Rodolfo F. de Wit, Ronald Mamtani, Ronac